About IEC

Home | About IEC | Faculty | Oncology | 正文

Jiwei Liu

Title: Professor Department Director
Email: jiweiliudl@126.com
Major: Oncology

Education/Professional Experience

Sep.1980-Jul.1986  Norman Bethune Medical University English class of Clinical medine,  bachelordegree

Sep.1986-Jul.1989  Norman Bethune Medical University Oncology,  Masterdegree

Sep.2001-Jul.2004  Dalian Medical University Molecular biology,  Ph.D.

Sep.1989.7up to now  The First Affiliated Hospital of Dalian Medical University Department of Oncology,Professor andDepartment Director

Jun.1998-Dec.1998 Japan KitakyushuMedical Center Cancer center,  Visiting scholar

Oct.2006-Mar.2007  Northwestern University, USA Robert Lurrie cancer center, Visiting scholar

Participation in the Academic Community

Standing Committee member of the Chinese society of Clinical Oncology (CSCO)

Committeemember of Chemotherapy, Chinese Anti-cancer Association

Vice Chairman of Small cell lung cancer expert committee-CSCO

Vice Chairman of Cancer Society of Liaoning Province, Chinese Medical Association

Vice Chairman of ChemotherapyCommittee,Liaoning Anti-cancer Association

Committeemember of Oncologist, Chinese Medical Doctor Association

Publication

1. Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation. PLOS ONE, 2014, 9 (12): e115401. IF:3.534, Corresponding author

doi: 10.1371/journal.pone.0115401. 

2. Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cells proliferation via decreasing of FUT4/LeY expression. Int J Oncol. 2015, 46 (4): 1667-76. IF:3.025, Corresponding author; doi: 10.3892/ijo.2015.2886. 

3. Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death. Int J Oncol. 2015, 47: 701-709. IF: 3.025, Corresponding author; doi: 10.3892/ijo.2015.3057.

4. Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.Cancer Biol Ther. 2015; 16 (2): 215-8. IF: 3.072, Corresponding author; doi: 10.4161/15384047.2014.962318.

5. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4. Oncotarget ,2016, 7(2):1619-1632.IF:6.359 ,Corresponding  author;DOI:10.18632/oncotarget.6451

6. Ginsenoside Rg3 induces FUT4-mediated apoptosis in H. pylori CagA-treated gastric cancer cells by regulating SP1 and HSF1 expressions. Toxicol In Vitro,  2016 ,31:158-166. IF:2.903, Co-corresponding author;DOI:10.1016/j.tiv.2015.09.025

7. Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG-2 hepatocellular carcinoma cells, 2015, MOLECULAR MEDICINE REPORTS,  Volume: 12; Issue: 1; Pages: 1598-1604; Impact Factor(JCR2014)  IF: 1.554, Co-corresponding author; DOI:10.3892/mmr.2015.3552

Research Projects/Grants

Principal Investigator of the National Natural Science Foundation of China-“Study on the mechanism of Rg3 on the effect of novel serum marker d-GM3 in the malignant melanoma metastasis”

Admission Plan/Requirements

One for Doctoral Candidate

One for Master’s Degree Candidate